Trovagene
Trovagene Enters Deal With Novogene for NextCollect in China
Novogene will validate Trovagene's proprietary urine collection and nucleic acid preservation device, NextCollect, and develop tests for the Chinese market.
Trovagene Inks Cancer Biomarker Deal With AstraZeneca
AstraZeneca will use Trovagene's Trovera EGFR urine liquid biopsy test in an open-label prospective biomarker study.
Trovagene Q4 Revenues Down, Company Restructuring to Expand Into Therapeutics
The firm announced a 14 percent drop year-over-year in fourth quarter revenues and plans to reduce personnel and other costs to support development of a precision drug it has licensed.
Trovagene Signs Deals to Distribute Liquid Biopsy Tests in Europe, Middle East
The distributors will promote Trovagene's clinical test services, and will also gain access to the research-use kits the firm is co-developing with Boreal Genomics.
Trovagene Reorganizes After Boreal Deal, Cuts 20 Jobs
The company believes that the reduction in staff and marketing costs for its testing services will reduce its annual pre-tax expenses by about $4 million.